Bitcoin price today: dips below $112k, near 6-wk low despite Fed cut bets
Joseph J. Wolk, Executive Vice President and CFO of Johnson & Johnson (NYSE:JNJ), sold 16,820 shares of company stock on August 15, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at an average price of $176.9067, with individual sales prices ranging from $176.87 to $177.015, totaling $2.97 million.
On the same day, Wolk exercised options to acquire 16,820 shares of Johnson & Johnson common stock at a price of $101.87 per share, for a total value of $1713453.
Following these transactions, Wolk directly owns 14,000 shares of Johnson & Johnson, and indirectly owns 68,835 shares held in a spousal lifetime access trust and 2,145 shares by 401k.
In other recent news, Johnson & Johnson has made several significant announcements. The company reported that it has launched the VIRTUGUIDE™ System, an AI-powered solution designed to support Lapidus procedures for bunion correction. This system has received FDA 510(k) clearance and uses pre-operative planning software to make personalized surgical recommendations. Additionally, Johnson & Johnson has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration to update the Tremfya label, supported by Phase 3b APEX study results showing reduced joint symptoms and inhibition of structural damage progression in psoriatic arthritis patients. The company is also seeking FDA approval for icotrokinra, a new oral drug for moderate to severe plaque psoriasis, based on successful Phase 3 clinical trials. In Europe, Johnson & Johnson’s Darzalex has received approval from the European Commission for use in treating high-risk smoldering multiple myeloma. Moreover, Erste Group has upgraded Johnson & Johnson’s stock rating from Hold to Buy, citing the company’s superior operating margin and return on equity compared to competitors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.